X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

Science of Hope: Learning from setbacks

By Andrew Powaleny  |    June 20, 2016
America’s biopharmaceutical research companies are committed to developing new treatments and cures that improve health and save patient lives. Jen O’Neil, principal oncology scientist at Merck,...   Read More

Advancing the science of hope

By Andrew Powaleny  |    June 13, 2016
Developing new medicines is a challenging undertaking, and the science is only getting harder. As our understanding of science grows, so does the complexity of developing new medicines,...   Read More

Cost of mental illness underscores need for new treatments

By Holly Campbell  |    May 25, 2016
Today, one in five American adults and children experience a mental illness in any given year. As the prevalence of complex mental health conditions has grown, the cost of caring for patients has...   Read More

Fighting blood cancers together at the 2016 Leukemia Ball

By Josephine Martin  |    March 11, 2016
Tomorrow, the Leukemia & Lymphoma Society (LLS) will hold one of Washington, D.C.’s largest charitable events: the 2016 Leukemia Ball. Since it began in 1988, the annual event has raised nearly...   Read More

FDA approves a record 45 new medicines in 2015

By Holly Campbell  |    January 11, 2016
Last year was an exceptionally strong year for biopharmaceutical innovation as the U.S. Food and Drug Administration (FDA) approved 45 new medicines – the highest number of approvals in almost two...   Read More

New PhRMA Report: Nearly 200 medicines in development for heart disease, stroke and other cardiovascular diseases

By Ieva M. Augstums  |    December 9, 2015
Despite significant decreases in death rates from heart disease and stroke over the past three decades, these two conditions continue to be leading causes of death in the United States. With more...   Read More

Fact Check Friday: The truth about Industry’s role in R&D

By Andrew Powaleny  |    October 23, 2015
As a follow-up to this blog we posted last year, PhRMA is excited to share new data that provides a fresh look at the significant investment of America’s biopharmaceutical companies make in R&D....   Read More

Week in Review: The Latest from PhRMA

By Priscilla VanderVeer  |    September 11, 2015
Medicines in Development: According to the latest Medicines In Development report, America’s biopharmaceutical research companies are currently developing 836 medicines and vaccines to treat...   Read More

The drug development and approval process is about much more than the final “okay”

By Tina Stow  |    August 24, 2015
A recent Forbes story not only presents an oddly limited look at the U.S.’s drug development process, it also sends a misleading message to America’s patients and health care professionals. “The...   Read More

New Report: Innovation in the Biopharmaceutical R&D Process – Adapting to a Changing Environment

By Anne McDonald Pritchett, PhD  |    June 30, 2015
With the average cost of developing, testing and receiving approval for a new medicine at $2.6 billion and rising, biopharmaceutical companies are continuously looking at new ways to increase...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates